Home / News / Pearce IP Blog
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
22 SEP 2023 | KR | Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing...
15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab)...
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical...
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the...
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that...
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.